NEWS CENTER

Anchoring Metrics for Strategic Implementation | Keyuan Group Holds a Special Training Session on the “1+2 Strategic Plan” and the Achievement of 2026 Budget Targets

Publish Time:

2026-01-20

On January 20, Keyuan Group held a special meeting in Jinan to discuss its “1+2 Strategic Plan” and the budget targets for 2026. Attending the meeting were Li Hongfu, Chairman of Keyuan Group; Gao Chunpo, President of Keyuan Pharmaceutical; Wei Zhiguo, President of Linuo Pharmaceutical; as well as the group’s core management team and key business personnel. With “strategy-driven leadership and practical implementation as the priority” at its core, the meeting systematically laid out the group’s future development strategy and the roadmap for implementing its annual budget. The meeting also featured the full-time guidance and commentary of Professor Lan Tao, a doctoral graduate from the National University of Defense Technology and an expert in corporate strategic management.

On January 20, Keyuan Group held a special meeting in Jinan to discuss its “1+2 Strategic Plan” and the budget targets for 2026. Attending the meeting were Li Hongfu, Chairman of Keyuan Group; Gao Chunpo, President of Keyuan Pharmaceutical; Wei Zhiguo, President of Linuo Pharmaceutical; as well as the group’s core management team and key business personnel. With “strategic leadership and practical implementation” at its core, the meeting systematically laid out the group’s future development strategy and the roadmap for implementing this year’s budget. The meeting also featured the full-time guidance and commentary of Professor Lan Tao, a doctoral graduate from the National University of Defense Technology and an expert in corporate strategic management.

The Chairman sets the tone: “One Body, Dual Cores, Dual-Engine Drive” — Anchoring on Three-Year Goals

The meeting kicked off with the solemn rendition of “The Song of Linuo” and the recitation of the Group’s mission, vision, and values. Chairman Li Hongfu delivered first the “Keyuan Group 1+2 Strategic Planning Report,” systematically outlining the Group’s strategic blueprint for the period from 2026 to 2028. Based on an in-depth review of both the global and Chinese pharmaceutical markets, the report employed analytical tools such as “Five Perspectives and Three Determinations” to clearly define the Group’s strategic positioning: “One Core, Dual Cores, and Dual-Engine Drive.” With chemical synthesis as a stable cornerstone and biomanufacturing as the engine for future growth, the Group will leverage the synergy between active pharmaceutical ingredients and finished dosage forms, while pursuing both organic growth and strategic investments and mergers and acquisitions. This approach will enable the Group to advance steadily and confidently in a complex market environment, gradually moving toward a higher-quality stage of development.

Dual-CEO Deployment: Refining the Path to Ensure Strategy Implementation

Next, the meeting moved on to a session focused on strategic decoding and implementation planning. Gao Chunpo, President of Keyuan Pharmaceutical, and Wei Zhiguo, President of Linuo Pharmaceutical, each delivered special reports centered on the two major business segments—active pharmaceutical ingredients and finished dosage forms—detailing how to align with the Group’s strategy, break down annual targets, and develop key initiatives and action plans. The reports focused on core issues such as market expansion, product planning, intelligent manufacturing, cost reduction and efficiency enhancement, and transformation of marketing models, aiming to precisely translate the Group’s strategy into actionable tasks for each business unit.

Expert Empowerment: Professor Lan Tao Provides Commentary and Guidance to Strengthen Implementation and Assurance.

This meeting took strategic deliberation and implementation planning as its core components. Under the chairmanship and guidance of Professor Lantao, participants conducted multiple rounds of in-depth brainstorming sessions and specialized discussions by department. Drawing on industry trends and the actual conditions of enterprises, Professor Lantao provided precise commentary and professional guidance on the strategic decoding approaches for each sector, helping the team further clarify key priorities, build consensus, identify actionable pathways, and effectively enhance the systematic nature and operational feasibility of the strategic plan.

In his concluding remarks, Chairman Li Hongfu emphasized that all employees should adhere to the belief of “letting metrics do the talking and going all out to ensure mission accomplishment,” firmly focus on our goals, take full responsibility, and turn strategic plans into tangible development outcomes.

Now that the blueprint has been drawn and consensus has been forged, with a clear course set and concerted efforts in place, the Group will continue to be guided by the values of “product-centricity, long-termism, and altruism.” We will systematically break down our strategic goals into actionable steps, steadily implement them, deepen our industrial layout, enhance our innovation capabilities, and achieve new breakthroughs in the field of bio-manufacturing. In this way, we will propel Kexuan Group toward high-quality, leapfrog development on the new journey of the 15th Five-Year Plan.

Weikang Bio visited Keyuan Pharmaceutical to jointly explore new pathways for pharmaceutical R&D!

Wang Bo and his delegation from Yaorongquan visited Kexuan Pharmaceutical to jointly explore industry trends and chart a new course for future development.

Weikang Bio visited Keyuan Pharmaceutical to jointly explore new pathways for pharmaceutical R&D!

Wang Bo and his delegation from Yaorongquan visited Kexuan Pharmaceutical to jointly explore industry trends and chart a new course for future development.